Stephen Welch

Stephen Welch will assume the role of President and CEO of Par Health following the close of the transaction. Currently, Mr. Welch serves as the Head of Specialty Generics at Mallinckrodt, a role he assumed in August 2022. Mr. Welch has executive responsibility for the Company’s Specialty Generics segment, directly managing all aspects of the segment’s business.

Previously, Mr. Welch served as the Senior Vice President and General Manager, Mallinckrodt Specialty Generics. He previously served as the segment’s Chief Financial Officer and Chief Transformation Officer for Mallinckrodt, including during the Company’s Chapter 11 process, and regularly represented the Company in those proceedings.

Mr. Welch joined Mallinckrodt in 2012 and has held a number of increasingly strategic roles, including Chief of Staff to the President and CEO and Vice President of Corporate Strategy. He began his time at Mallinckrodt in the tax department, focusing primarily on M&A transactions and business integrations.

Prior to joining Mallinckrodt, Mr. Welch led the tax functions at Human Genome Sciences, Inc., a formerly publicly listed biopharmaceutical company and PharMerica Corporation, a pharmacy services provider. He began his career at PricewaterhouseCoopers.

Mr. Welch holds a Juris Doctor from the Georgetown University Law Center and a Bachelor’s degree in Political Science from California State University, Bakersfield. In 2023, Mr. Welch completed Harvard Business School’s Advanced Management Program.